Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Capital Investment Advisory Services LLC

Capital Investment Advisory Services LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,954 shares of the biopharmaceutical company's stock after selling 2,558 shares during the quarter. Capital Investment Advisory Services LLC's holdings in Gilead Sciences were worth $779,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences during the first quarter valued at $25,000. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences during the first quarter valued at $29,000. Annis Gardner Whiting Capital Advisors LLC grew its position in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 216 shares during the period. Lee Danner & Bass Inc. acquired a new stake in Gilead Sciences during the fourth quarter valued at $41,000. Finally, Investment Research & Advisory Group Inc. grew its position in Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the sale, the chief financial officer directly owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. The trade was a 1.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the completion of the sale, the chief executive officer directly owned 615,725 shares in the company, valued at $68,006,826.25. This trade represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 58,500 shares of company stock valued at $6,340,745. Company insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

GILD has been the topic of several analyst reports. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Morgan Stanley lifted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Finally, Oppenheimer dropped their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Trading Down 0.2%

GILD stock traded down $0.24 during trading on Friday, reaching $111.28. 4,039,811 shares of the stock were exchanged, compared to its average volume of 7,706,267. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The business has a 50 day moving average price of $107.02 and a 200-day moving average price of $104.02. Gilead Sciences, Inc. has a 1 year low of $66.34 and a 1 year high of $119.96. The firm has a market capitalization of $138.42 billion, a price-to-earnings ratio of 23.43, a P/E/G ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the firm earned ($1.32) earnings per share. Gilead Sciences's quarterly revenue was down .3% compared to the same quarter last year. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.